The analyst also notes that the company has been in the wound market since 1998, becoming "one of the largest pure-play companies in the fast growing and underpenetrated Advanced Wound Care market." Zimmerman further points to Organogenesis having built a $200M revenue business with its "stalwart wound products Apligraf
and Dermagraft", with faster growing PuraPly for early wound intervention, and believes that it can capture more market share from some of its struggling competitors.
While Stratagraft is primarily employed to treat burn wounds, Apligraf
is used to treat leg and diabetic foot ulcers.
Moreover, bioengineered skin substitutes such as Dermagraft and Apligraf
can aid in the healing of venous ulcers.
The company's products include Apligraf
The company's FDA-approved bioengineered living cell-based therapies, Apligraf
and Dermagraft, have also experienced strong sales growth, with more than 1 million units of Apligraf
and Dermagraft shipped for patient applications to date.
M2 EQUITYBITES-November 4, 2015-Swissmedic grants marketing authorisation to Organogenesis' Apligraf
M2 PHARMA-November 4, 2015-Swissmedic grants marketing authorisation to Organogenesis' Apligraf
Several artificial skin products were already available on the more advanced wound management market, such as Dermagraft, Apligraf
, TheraSkin, TransCyte, Laserskin, Epicel, OrCel, and Hyalograft.
These include MAC1 (Aastrom Biosciences), LAVIV (Fibrocell Bioscience), Apligraf
, Gintuit (Organogenesis Inc.) etc.
There are regenerative medicines used to regenerate tissue, with products such as Organogenesis' Dermagraft and Apligraf
, and Aastrom's Carticel and TiGenix's ChondroCelect, which regenerate and replace cartilage.
Falanga, "Tissue engineering and the development of Apligraf
, a human skin equivalent," Cutis; Cutaneous Medicine for the Practitioner, vol.